🚨 84.4% CLINICAL BENEFIT? THIS IVERMECTIN + MEBENDAZOLE STUDY IS GETTING ATTENTION A new real world study looked at Ivermectin + Mebendazole in cancer patients and reported an 84.4% clinical benefit rate after six months. The study included 197 cancer patients, with 122